Adamas Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adamas Pharmaceuticals, Inc.
Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.
The latest US FDA approval news from the Pink Sheet’s US FDA Performance Tracker
Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
- Controlled Release
- Drug Delivery
- Other Names / Subsidiaries
- Osmotica Pharmaceutical US
- Supernus Pharmaceuticals, Inc.